Dr. Fang Jianmin, served as the company’s director from October 2008 to April 2020, and has served as the company’s executive director since May 2020. He is mainly responsible for the company’s overall management, business and strategic planning, and is fully responsible for the company’s drug research and development.

Dr. Fang has been engaged in novel drug research and development for more than 20 years. He has experience in leading multiple innovative biological drugs from early discovery to commercialization. He has more than 50 drug-related invention patents. He received his PhD in biology from Dalhousie University in Canada in May 1998 and served as a Post-Doctoral Fellow in the Department of Surgery, Harvard Medical School/Boston Children’s Hospital from 1997 to 2000.

Dr. Fang served as a member of overall expert group for the national significant science and technology project “Significant New Drug Creation” during the “Twelfth Five-Year Plan” and the “Thirteenth-Five-Year Plan” period. He was awarded the “National Distinguished Expert” by the Organization Department of the Central Committee of the Communist Party of China, the “Taishan Scholar” of Shandong Province, and the “Qilu Outstanding Talent Award” etc. Currently, he is a professor and doctoral supervisor at the School of Life Sciences and Technology, Tong Ji University.